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Abstract
Background: Although most diabetic patients do not achieve good physiologic control, patients
who live closer to their source of primary care tend to have better glycemic control than those
who live farther away. We sought to assess the role of travel burden as a barrier to the use of
insulin in adults with diabetes
Methods: 781 adults receiving primary care for type 2 diabetes were recruited from the Vermont
Diabetes Information System. They completed postal surveys and were interviewed at home.
Travel burden was estimated as the shortest possible driving distance from the patient's home to
the site of primary care. Medication use, age, sex, race, marital status, education, health insurance,
duration of diabetes, and frequency of care were self-reported. Body mass index was measured by
a trained field interviewer. Glycemic control was measured by the glycosolated hemoglobin A1C
assay.
Results: Driving distance was significantly associated with insulin use, controlling for the covariates
and potential confounders. The odds ratio for using insulin associated with each kilometer of
driving distance was 0.97 (95% confidence interval 0.95, 0.99; P = 0.01). The odds ratio for using
insulin for those living within 10 km (compared to those with greater driving distances) was 2.29
(1.35, 3.88; P = 0.02).
Discussion: Adults with type 2 diabetes who live farther from their source of primary care are
significantly less likely to use insulin. This association is not due to confounding by age, sex, race,
education, income, health insurance, body mass index, duration of diabetes, use of oral agents,
glycemic control, or frequency of care, and may be responsible for the poorer physiologic control
noted among patients with greater travel burdens.
Background
In spite of the widespread availability of efficacious thera-
pies, adequate management of diabetes remains an elu-
sive goal [1,2]. Barriers to optimum control of diabetes in
community settings include poor practice management
and organization [3-5], poor adherence to medical advice
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by patients [6], comorbid illnesses [7], and lack of health
insurance [8]. Although appropriate use of insulin can
lead to better glycemic control, as well as a better self-
reported quality of life [9], many patients and providers
underutilize insulin for a variety of reasons, including
clinical inertia [10] and medical concerns [11].
Geography has long been recognized as a determinant of
health status. For example, cerebrovascular disease clus-
ters in the "stroke belt" of the southeastern United States
[12]. Death rates among European elders vary two-fold
depending on place [13]. Americans are more likely to be
disabled in certain parts of the country than others
[14,15].
Recently, use of Geographic Information Systems has led
to insight about spatial prevalence and treatment of many
conditions including diabetes [16,17]. Geographic pat-
terns of health care utilization have also revealed impor-
tant variations in treatment patterns of various conditions
among even small geographic areas [18,19]. Mammogra-
phy [20], knee joint replacement [21], treatment of color-
ectal cancer [22], and lower extremity amputation [23], to
name a few examples, have all been shown to vary impor-
tantly by geographic location of the population independ-
ent of clinical status at the individual level.
To some degree, these variations may be due to variation
among the providers (both individual and institutional)
whose various practice styles can introduce patterns of
care that vary at the geographic level [24]. However, in
some cases there is evidence that local geography can,
itself, serve as a barrier to care. Travel burden, measured as
driving distance or access to transportation, has been
linked to health care utilization [25-27]. In diabetes care
specifically, increased travel burden, as measured by driv-
ing distance, has been associated with poorer glycemic
control [28].
Modern Geographic Information Systems (GIS) make it
relatively inexpensive to determine the most direct driving
route between two known addresses. For rural areas,
where routes are often circuitous, driving distance has
been shown to be a more accurate marker of travel burden
than straight-line measures [29].
In this study, we examined the relationship between insu-
lin usage and the driving distance from a patient's home
to their site of primary care. We sought to evaluate the
hypothesis that insulin use is associated with driving dis-
tance and to evaluate whether any observed relationship
was due to confounding by social, economic or clinical
factors.
Methods
This study was part of a larger project, the Vermont Diabe-
tes Information System (VDIS), a cluster-randomized trial
of a laboratory-based diabetes decision support system in
a region-wide sample of 7406 adults with diabetes from
73 primary care practices [30]. VDIS delivers improved
laboratory information services to patients and providers
to support and enhance their decision making about dia-
betes treatment and monitoring. The data presented here
were collected at baseline before the VDIS intervention
began. A field survey targeted at a sub-sample of subjects
was designed to provide a better understanding of the
non-laboratory features of the patients. Subjects were
selected at random from the patients participating in the
VDIS trial and invited by phone to participate in an in-
home interview. Patient names were randomly sorted and
patients contacted by telephone until a sample of approx-
imately 15% of the patients from each practice agreed to
an interview. If a subject could not be contacted, another
name was chosen from the list. Therefore, many subjects
were called only once or twice before being excluded from
the study. We attempted to contact 4,209 patients and
reached 1,576 (37%). Of these, 1,006 (64%) agreed to be
interviewed.
Subjects who agreed were mailed a questionnaire and
were scheduled for an interview by a trained field inter-
viewer. The questionnaire covered multiple domains
including demographics and medication usage. During
the visit, the interviewer reviewed any missing or ambigu-
ous questionnaire items. If necessary, the interviewer read
the questions aloud for subjects and recorded their
responses for them. Then the interviewer measured the
subject's height, weight and blood pressure. The subjects
were asked to produce every medicine they had used in
the past month for the interviewer to record. The inter-
views took place during the baseline phase of the study
before any interventions were in place. The protocol was
approved by the institutional review board of the Univer-
sity of Vermont.
Income was recorded in seven ordered self-reported cate-
gories from less than $15,000 per year to $100,000 per
year or more. For analysis, we collapsed these into two cat-
egories: above and below $30,000 per year. We collapsed
self-reported education into High School Graduate or not.
We collapsed self-reported race and ethnicity into two cat-
egories: Non-Hispanic white and all others. Marital status
was collapsed into two categories: married (including liv-
ing as married) and all others (single, widowed, divorced
or separated). We recorded the presence or absence of five
categories of health insurance: private (commercial
indemnity or health maintenance organizations), Medi-
care, Medicaid, military (including active duty or Veterans
benefits) and uninsured. Subjects were asked to recall theBMC Public Health 2006, 6:198 http://www.biomedcentral.com/1471-2458/6/198
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number of visits they made to their primary care provider
(PCP) in the last month and whether they had seen an
endocrinologist in the last year. Glycemic control was esti-
mated by the latest glycosolated hemoglobin A1C assay
performed at the local clinical laboratory.
We included all interviewed subjects who provided com-
plete data for all variables. Subjects were excluded from
analysis as potentially having type 1 diabetes if they used
insulin without any oral hypoglycemic agents and were
diagnosed with diabetes before age 30. We compared the
characteristics of the included subjects to all interviewed
but excluded subjects using t-tests, χ2 tests and Fisher exact
tests.
The shortest driving distance from the patients' homes to
their site of care was calculated in kilometers using
ArcView 3.3 by Environmental Systems Research Institute,
Inc., and a geographic data set of roads purchased from
TeleAtlas, Inc. Locations were geocoded by matching
addresses to the street layer, which is coded with address
ranges. Driving distance was defined as the shortest dis-
tance along roads and highways. We also categorized sub-
jects dichotomously as living less than or greater than 10
km from their PCP (10 km = 6.2 miles).
We compared the driving distances of insulin users and
non-users with the Wilcoxon rank-sum test and the χ2 test.
We divided observations by their driving distance into
four quartiles and compared the insulin use for each quar-
tile. We tested the significance of the trend in insulin use
across quartiles with a nonparametric extension of the
Wilcoxon rank-sum test [31]. Because nonparametric pro-
cedures are not available, we used analysis of variance
(ANOVA) to test for clustering of factors within providers'
practices and expressed this phenomenon as the intra-
provider (or intra-cluster) correlation coefficient (ICC)
[32]. We used logistic regression to test the association
between insulin use (present or absent) and each marker
of travel burden (distance in kilometers and the dichoto-
mous variable) by calculating odds ratios (OR) and their
95% confidence intervals (CI). We repeated the analysis
controlling for age, sex, race, education, income, health
insurance, body mass index, use of any oral hypoglycemic
agents, glycemic control, and duration of diabetes in
years. We adjusted the standard errors and significance
values of the multivariate analyses for clustering within
provider practices [33]. We used Stata 8.2 for all analyses.
Results
Description of population
The analysis included 781 patients from 68 practices who
completed the interview without missing values for any of
the covariates, had an address that could be geographi-
cally referenced, and did not meet criteria for type 1 dia-
betes. They were predominantly elderly (51% age 65 or
more), female (54%), white (97%), and married (63%).
Seventy-six percent had graduated high school and 57%
earned less than $30,000 per year. Most had some form of
health insurance. 136 subjects (17%) used insulin and
666 did not. Excluded subjects had a longer duration of
diabetes, less use of insulin, greater use of oral hypoglyc-
emic agents and Medicare health insurance, lower BMI,
and somewhat lower incomes. See Table 1.
Vermont and the neighboring regions where the subjects
lived are largely rural or exurban (a pattern of fragmented,
low-density residential development relatively far from
traditional urban centers, but not associated with agricul-
tural or other extractive land uses [34]). Vermont has 240
physicians including 86 Primary Care Physicians per
100,000 population. These are higher than the US
national averages of 198 physicians and 69 primary care
physicians per 100,000 population [35]. The median driv-
ing distance was 5.3 km (4.8 miles) with over 90% of the
respondents living within 30 km (18.8 miles) of their
PCP.
Bivariate association of driving distance and insulin use
Insulin users had shorter driving distances than non-users
when considering the mean (13.0 km vs. 9.2 km) or virtu-
ally any percentile of the driving distance distributions (P
= 0.005; see Table 2). Figure 1 shows the distribution of
driving distances for users and non-users of insulin. Those
living greater than 10 km away were less likely to use insu-
lin than those living nearer (11.9% vs. 20.1%, P = 0.002).
This relationship was also demonstrated by unadjusted
logistic regression. The odds ratio for insulin use associ-
ated with each kilometer of driving distance was 0.98 (CI
0.96, 0.99; P = 0.01). The OR for living within 10 km was
1.88 (CI 1.25, 2.82; P = 0.003). The proportion of subjects
using insulin decreased monotonically from the nearest
quartile of subjects (22%) to the quartile with the greatest
driving distance (10%, P = 0.004). See Figure 2.
Bivariate consideration of potential confounders
Insulin users were more often male (48% vs. 37%, P =
0.03), had higher body mass indices (36 vs. 34 kg/m2, P =
0.001) and had been diabetic longer (16 vs. 8 years, P <
0.001). They were seen in primary care more often (2.1 vs.
1.5 visits per month, P < 0.001) were more likely to see
specialty providers (37% vs. 11% seen in last year, P <
0.001), less likely to use oral hypoglycemic agents (57%
vs. 72%, P < 0.001) and were more likely to earn less than
$30,000 per year (66% vs. 56%, P = 0.03). Other differ-
ences between users and non-users did not achieve statis-
tical significance. See Table 3.
Although insulin users lived closer to their providers and
had more visits than non-users, there was no significantBMC Public Health 2006, 6:198 http://www.biomedcentral.com/1471-2458/6/198
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relationship between PCP visits and driving distance.
Expressed as a continuous variable in km, the rank-sum
correlation of distance with the number of PCP visits in
the last month was -0.03 (P = 0.46). Likewise, the number
of visits was similar in those living within 10 km and their
more distant counterparts (1.6 vs. 1.5 visits per month, P
= 0.63).
Similarly, there was little difference in travel burden to
primary care for those seeing an endocrinologist com-
pared to those who did not (12.1 vs. 12.4 km, P = 0.72).
The use of an endocrinologist was similar among those
who lived within 10 km of their PCP and those who did
not (15% vs. 17%, P = 0.39).
To explore the possibility that confounding by provider
style is responsible for the apparent association between
travel distance and insulin, we calculated the intra-pro-
vider correlation coefficients for both travel distance and
insulin use. Insulin use was not significantly variable
among providers (ICC = 0.004, P = 0.41). However, there
was significant clustering of travel distance by provider
(ICC = 0.18, P < 0.001). In other words, some providers
tended to have patients who live far away while others
tended to have more local practices.
Multivariate model to control for potential confounders
After adjusting for age, sex, race, marital status, education,
income, health insurance, body mass index, duration of
diabetes, glycemic control, use of oral hypoglycemic
agents, number of visits to the PCP and consultation with
an endocrinologist, the OR for using insulin associated
with each kilometer of driving distance was 0.97 (CI 0.95,
0.99; P = 0.013). See Table 4. The OR for using insulin for
those living within 10 km was 2.29 (CI 1.35, 3.88; P =
0.002). See Table 5.
Discussion
The greater the driving distance for adults with diabetes to
their source of primary care, the less likely they are to be
using insulin. This relationship is not due to confounding
Table 2: Driving distances of insulin users and non-users
Percentile Insulin
Users (n = 136)
Non-Users
(n = 666)
0th (Minimum) 0.4 0.1
10th 0.6 1.4
25th 2.3 2.7
50th (Median) 5.3 8.3
75th 11.7 17.0
90th 20.0 29.5
100th (Maximum) 51.9 340.4
All distances are in kilometers.
Table 1: Population characteristics of 781 included and 225 excluded subjects
Characteristic Included Excluded P
Age (years) 64.68 (22–93) 65.6 (30–89) 0.16
Senior citizen 51.3% 57.5% 0.11
Male 46.1% 44.6% 0.70
Race – White, non-Hispanic 97.1% 98.1% 0.41
Married or living as married 62.7% 60.9% 0.64
Education – High School Graduate 76.3% 72.3% 0.24
Income less than $30,000 per year 57.7% 66.0% 0.07
Health Insurance
Private 58.3% 59.1% 0.82
Medicare 58.1% 66.7% 0.03
Medicaid 20.9% 22.8% 0.56
Military or Veterans' 5.0% 6.5% 0.41
None 2.3% 2.8% 0.65
Body Mass Index (kg/m2) 34.1 (16–65) 32.7 (18–68) 0.01
Duration of diabetes (years) 9.4 (0.02–61) 14.3 (0.03–62) <0.001
Glycosolated hemoglobin A1C (%) 7.1 (4.7–13.5) 7.1 (4.0–12.9) 0.67
Glycosolated hemoglobin A1C less than 7% 57.9% 58.9% 0.44
Primary care visits in the last month (visits) 1.6 (0–25) 1.7 (0–16) 0.85
Endocrinology visit in the last year 14.9% 20.0% 0.08
Insulin use 16.8% 25.0% 0.01
Oral agent use 69.4% 57.1% 0.001
Travel burden
Driving distance (km) 12.4 (0.1–340) 12.2 (0.1–59) 0.78
Driving distance less than 10 km 59.0% 56.3% 0.51
Some respondents reported more than one type of health insurance. The sample sizes for excluded subjects vary as some characteristics had 
missing values. There are no missing values for the included subjects. P values calculated by Wilcoxon rank-sum or χ2 tests as appropriate.BMC Public Health 2006, 6:198 http://www.biomedcentral.com/1471-2458/6/198
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by the social, demographic, or clinical factors measured
here.
The mechanism for this relationship is unclear. Perhaps
patients and physicians are concerned about the risks of
insulin and are reluctant to use it if they feel the patient
lives too far away from care for rescue in the event of
hypoglycemia. We have no direct data on the attitudes of
these decision makers in this regard.
Perhaps patients with more visits can be stepped through
the various regimens more promptly and started on insu-
lin sooner. In other words, travel burden might influence
therapy through the frequency of medical contact. How-
ever, we found little relationship between distance and
visit frequency. Furthermore, adjusting for frequency of
visits (either to primary or specialty care) had little effect
upon the relationship between distance and insulin use.
Possibly, providers who systematically avoid insulin in all
their patients systematically attract patients from farther
afield. This is unlikely given the low clustering of insulin
use within providers and the minimal impact of correct-
ing for clustering in the multivariate analyses. Although
providers do systematically vary in the size of their catch-
ment areas, they do not appear to have systematic tenden-
cies to use or avoid insulin.
Previous findings suggest that patients who travel farther
to primary care have poorer physiologic control [28].
Likewise, rural patients, who generally have higher travel
burdens, tend to have poorer health status [36]. It is not
known if these effects are completely explained by lower
intensity of therapy. Nonetheless, it speaks to the need to
reassess care for rural and exurban patients. Several possi-
ble approaches come to mind. Medical services, especially
primary care, could be dispersed more widely. Although
the economic and cultural barriers to placing physicians
in underserved areas are formidable [37], greater use of
home or worksite visits by traveling or circuit providers
(physicians, nurses, physician assistants, etc.) could be
attractive. Also, new technologies could replace or com-
plement traditional face-to-face personal care. The tele-
phone, facsimile, and the Internet have potential to
alleviate the barriers associated with distance in health (as
they have for business, education, government and other
endeavors) [38]. However, current insurance reimburse-
ment schemes generally discourage services that are not
provided in person.
Limitations
Because the study population was drawn from primary
care practices in mostly rural and exurban regions of Ver-
mont, New Hampshire, and New York, the population
was mostly white and insured. The results may not gener-
alize to urban patients or populations with poor financial
access to care. Conversely, patients in lower density areas
of America (such as the Great Plains or rural Alaska) may
have significantly longer driving distances to access pri-
mary care.
Although we controlled for a number of potentially con-
founding variables, residual confounding by unmeasured
Distribution of driving distances for insulin users and non- users Figure 1
Distribution of driving distances for insulin users and 
non-users. The middle line of each box represents the 
median driving distance. The boxes span the inter-quartile 
range of driving distances from the 25th to the 75th percen-
tiles. The whiskers span the outer quartiles. Outlier or out-
side values are excluded so that the medians and quartiles 
can better be compared.
0
10
20
30
40
D
r
i
v
i
n
g
 
d
i
s
t
a
n
c
e
(
k
m
)
Non-users Insulin users
Insulin use over the range of driving distances Figure 2
Insulin use over the range of driving distances. Driving 
distances were divided into quartiles of 195 or 196 subjects 
each. The heights of the bars represent the proportion of 
subjects in each quartile who use insulin.
0.22
0.18 0.17
0.10
0
.05
.1
.15
.2
.25
P
r
o
p
o
r
t
i
o
n
 
o
f
s
u
b
j
e
c
t
s
 
u
s
i
n
g
i
n
s
u
l
i
n
<2.6 2.60-7.68 7.69-16.54 >16.54
Driving Distance (km)BMC Public Health 2006, 6:198 http://www.biomedcentral.com/1471-2458/6/198
Page 6 of 8
(page number not for citation purposes)
variables could account for some or all of the observed
relationship between driving distance and insulin use.
We measured travel burden as the driving distance from
home to the PCP. However, some patients may travel to
their PCP from work or another location, receive home
visits, have more or less difficult travel routes, or face very
different travel burdens due to handicap or access to trans-
portation services. Similarly, geocoding (the process of
assigning a geographic location to an address) is subject to
random error, which may be larger in rural than urban
areas [39]. Unless these factors are associated with both
distance from home as we measured it and insulin use,
they are unlikely to bias our estimates. Indeed, they would
be expected to contribute random error and reduce the
statistical significance of the analyses.
Although we recruited the subjects from primary care
practices, some subjects may have been receiving their
diabetes care from a specialist and would therefore be
more likely to be using insulin. Although these patients
presumably travel farther on average to the specialist, it is
unlikely that they systematically travel a shorter distance
to primary care.
Although we eliminated subjects who apparently have
type 1 diabetes, there are no perfectly reliable criteria for
distinguishing type 1 from type 2 diabetes in this setting.
Repeating the analyses with the 23 type 1 subjects
included had little effect on the results, suggesting that the
possible inclusion of some type 1 patients would not be
consequential.
The models do not include all variables that may have a
role in explaining the use of insulin. Such an exercise is
beyond the scope of this report. Rather, we sought only to
test the hypothesis that insulin use and driving distance
are independently related. Therefore, we included only
those variables that could confound the apparent rela-
tionship between insulin use and driving distance.
Conclusion
Adults with type 2 diabetes who live farther from their
source of primary care are less likely to use insulin. This
association is not due to confounding by age, sex, race,
education, income, health insurance, body mass index,
duration of diabetes, use of oral hypoglycemic agents, or
frequency of primary or specialty care and may be respon-
sible for the poorer physiologic control noted in rural
patients.
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Table 3: Social, geographic, and clinical correlates of insulin use (univariate comparisons)
Characteristic Proportion or mean and range P
Insulin Users
(n = 131)
Non-Users
(n = 650)
Travel burden
Driving distance (km) 9.38 (0.4–52) 13.0 (0.1–340) 0.005
Driving distance less than 10 km 71.0% 56.6% 0.002
Age (years) 65.5 (36–88) 64.4 (22–93) 0.36
Male 37.40% 47.9% 0.03
Race – White, non-Hispanic 96.2% 97.2% 0.52
Married or living as married 60.3% 63.2% 0.53
High School Graduate 77.9% 76.0% 0.65
Income less than $30,000 per year 65.7% 56.2% 0.045
Health Insurance
Private 59.6% 58.0% 0.74
Medicare 63.4% 57.1% 0.18
Medicaid 22.9% 20.5% 0.53
Military or Veterans' 6.9% 4.6% 0.28
None 1.5% 2.5% 0.52
Body Mass Index (kg/m2) 35.9 (18–53) 33.8 (16–65) 0.001
Duration of diabetes (years) 16.0 (0.1–44) 8.1 (0.02–61) <0.001
Glycosolated hemoglobin A1C (%) 7.8 (5.4–13.3) 7.0 (4.7–13.5) <0.001
Glycosolated hemoglobin A1C < 7% 36.6% 62.2% <0.001
Oral hypoglycemic agent use 57.2% 71.9% 0.001
Endocrinology visit in the last year 36.6% 10.5% <0.001
Primary care visits in the last month 2.1 (0–20) 1.5 (0–25) <0.001BMC Public Health 2006, 6:198 http://www.biomedcentral.com/1471-2458/6/198
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